Results 151 to 160 of about 101,598 (260)
Granulocyte Colony-Stimulating-Factor-Producing Bladder Carcinoma: A Case Report and Literature Review. [PDF]
Yamashita K +7 more
europepmc +1 more source
Elucidating the contribution of gut‐organ axes will provide new insights for developing combined therapeutic strategies against sepsis‐associated multiple organ dysfunction. ABSTRACT Sepsis, a life‐threatening clinical syndrome precipitated by a maladaptive host response to infection, is associated with substantial morbidity and high mortality rates ...
Yichen Bao +7 more
wiley +1 more source
Clinical Insights Into Aortitis Following Granulocyte Colony-Stimulating Factor Use in an Older Male Patient. [PDF]
Sugihara K +3 more
europepmc +1 more source
A presumed case of pulmonary alveolar proteinosis with clinical deterioration was ultimately identified at autopsy as pneumonic‐type pleomorphic carcinoma. This case highlights the diagnostic overlap between diffuse lung diseases and the risk of anchoring bias in critically ill patients.
Dakota Wheeler +3 more
wiley +1 more source
Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial. [PDF]
Wang H +9 more
europepmc +1 more source
The different face of skin‐rash induced by brentuximab vedotin
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri +11 more
wiley +1 more source
Granulocyte colony-stimulating factor-producing cutaneous squamous cell carcinoma: A case report and literature review. [PDF]
Ishiguro A +3 more
europepmc +1 more source
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner +12 more
wiley +1 more source
Acute Lung Injury in a Healthy Peripheral Blood Stem Cell Donor Following Granulocyte-colony Stimulating Factor Administration: A Case Report. [PDF]
Desai N +5 more
europepmc +1 more source
ABSTRACT Objectives Genetic rare diseases (GRDs), including chronic granulomatous disease, familial hemophagocytic lymphohistiocytosis, and congenital neutropenia, often require hematopoietic stem cell transplantation (HSCT) as the only curative option.
Bo Kyung Kim +6 more
wiley +1 more source

